Autumn babies at greater risk of asthma: study Nov 21, 2008
Vaccine makers GenVec Inc, AstraZeneca's MedImmune unit and others are working on RSV. "It's in the pipeline. We just don't have one yet," Hartert said. (Scientific American)
GenVec reports promising test results Nov 19, 2008
GenVec reports promising results from drug tests - Washington Business Journal ... GenVec reports promising results from drug tests ... GenVec s pancreatic cancer treatment, which won fast-track review from the Food and Drug Administration just a week ago, is showing promise in its latest trial. (Washington Business Journal, DC)
GenVec wins fast-track from FDA Nov 11, 2008
While GenVec has been developing TNFerade to fight a range of cancers, the FDA has awarded the fast-track status specifically toward the treatment of locally advanced pancreatic cancer ... As further data emerge regarding TNFerade, we look forward to working closely with the FDA to potentially expedite the review process for TNFerade, said Mark Thornton, senior vice president of product development at GenVec (NASDAQ: GNVC). (Washington Business Journal, DC)
GenVec reports $6.5 million loss Aug 8, 2008
GenVec also reported nearly $3 ... That money was enough to offset decreased revenue from GenVec s HIV vaccine program ... GenVec (NASDAQ: GNVC) holds $31 million in cash as of June 30, including $2. (Washington Business Journal, DC)
GenVec to sell $17M of stock, warrants Jun 8, 2008
Under the deal, which is set to close by Wednesday, GenVec has allowed investors to buy one share and a warrant to buy one-fifth of a share of common stock for $1 ... After expenses, GenVec expects to bring back $15 ... In February 2007, GenVec had filed with the Securities and Exchange Commission to initiate a $100 million shelf registration -- essentially register and shelve $100 million worth of shares that could be sold when the company needed cash. (Washington Business Journal, DC)
Gaithersburg biotech looking for new HQ Jun 2, 2008
GenVec is entering a stage of drug development that most biotechs aspire to from their earliest lab-bench days ... Richard M. Rhodes, managing principal for CresaPartners LLC, a real estate firm representing GenVec, said the company is still narrowing down locations to pursue. (Baltimore Business Journal, MD)
Genvec wins third grant from NIH this year May 8, 2008
Genvec, which reported a 26 percent drop in revenue last year as a research project came to an end, has secured new funding for its vaccine development. Gaithersburg-based Genvec Inc. (NASDAQ: GNVC) announced Wednesday that it has received a two-year, $600,000 grant from the National Institute of Allergy and Infectious Diseases, part of the ... This is the third $600,000 NIH grant Genvec has secured in 2008. (Washington Business Journal, DC)
Genvec wins $600,000 grant Apr 3, 2008
Gaithersburg-based Genvec Inc. announced Thursday that it has received a $600,000 from the for work on a malaria vaccine. Genvec, which is also working on vaccines to fight cancer, flu and genital herpes, said the money is a Small Business Innovation and Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases of NIH. The two-year grant will be used to develop enhancements to Genvec's adenovector technology for vaccine applications against malaria ... "In addition to... (Washington Business Journal, DC)
Patient's Plea: Fight Cancer With Star Power Mar 27, 2008
In the Loughman's case, GenVec, the company testing the cancer drug, denied the Loughman's request. Robert Young, chancellor of Fox Chase Cancer Center in Philadelphia, emphasized why companies don't always give the green light. (ABC News)
GenVec reports narrowed losses Mar 15, 2008
For all of 2007, GenVec made $14 million in revenue and reported an $18 ... GenVec's drop in revenue between 2006 and 2007 stemmed from its completion of a contract to supply the Vaccine Research Center with HIV vaccine supplies for the center's clinical trials ... Also, GenVec saw another cancer therapy funding collaboration with Japanese-based Fuso Pharmaceutical Industries expire at the end of 2006. (Washington Business Journal, DC)
Merck AIDS Failure Signals Doom for Africa, U.S. Projects to Prevent HIV Jan 31, 2008
The government vaccine contains a cold virus made by Gaithersburg, Maryland-based GenVec Inc. and a DNA vaccine made by San Diego-based Vical Inc. It has at least two features in common with Merck's. First, while most vaccines spur the body to make protective proteins called antibodies, the experimental AIDS shots stimulate protective T-cells, white cells the immune system uses to attack viruses. (Bloomberg -- US)
GenVec names new member to board, audit committee Jan 21, 2008
"Kevin's extensive experience and insights into the commercialization of pharmaceutical products will add strength to our board," said GenVec chief executive Paul Fischer in a statement ... At GenVec, he will get a $5,000 retainer per quarter, $2,000 per board meeting attended and $1,000 per committee meeting attended ... In the company's most recent quarterly statement, GenVec (NASDAQ: GNVC) said it cut its losses to $4. (Washington Business Journal, DC)
GenVec wins more funding for HIV vaccines Oct 20, 2007
GenVec (NASDAQ: GNVC) said it has given 1,400 volunteers in 14 clinical trials its Ad5 HIV vaccine. Along with the HIV vaccines, GenVec is also developing a vaccine to prevent foot-and-mouth disease from breaking out in the U.S. under a three-year contract with the Department of Homeland Security. (Washington Business Journal, DC)
V-Empower, Inc. Tops Deloitte's Maryland Technology Fast 50 Ranking of Fastest-Growing Technology Companies, With 9,268 Percent Growth Over Five Years Oct 3, 2007
com Bethesda 302% 23 NETCONN Solutions Hagerstown 284% 24 Vocus, Inc. Lanham 250% 25 Tresys Technology, LLC Columbia 243% 26 TVI Corporation Glenn Dale 225% 27 Chesapeake Research Review, Inc. Columbia 221% 28 Metastorm, Inc. Baltimore 182% 29 CNSI Rockville 181% 30 Universal Security Instruments, Inc. Owings Mills 176% 31 Gryphon Technologies, LC Greenbelt 174% 32 Optelecom, Inc Germantown 165% 33 Barcoding Inc. Baltimore 159% 34 Advanced Concepts, Inc. Columbia 151% 35 Infinite Computer... (PR Newswire)
Md. biotech to develop malaria vaccine for military Sep 12, 2007
GenVec (NASDAQ: GNVC) is already working with the Military Malaria Vaccine Program on vaccines for P. falciparum, the most deadly strain of malaria. sba2007 { width:604px; border:3px solid #ccc9be; background:#fff; margin:15px 0 5px 0; padding:0; } #sba2007 h3 { margin:0; font:bold 15px/15px arial; text-transform:none; padding:6px 10px; background:#f1ede2; color:#900; display:block; } #sba_inner {margin:6px 10px 6px 10px; font:normal 12px arial; float:left;} #sba_inner p {margin:0 0 5px 0;... (Bizjournals.com)
GenVec Up on Malaria Vaccine Contract Sep 11, 2007
Biopharmaceutical company GenVec Inc. said Monday it agreed to develop a malaria vaccine candidate against Plasmodium vivax with the U.S. Military Malaria Vaccine Program at the Walter Reed Army Institute of Research and the Naval Medical Research Center ... In addition, GenVec (nasdaq: - - ) signed a one-year contract with the Department of Defense to construct and test an adenovector-based vaccine, which carries a new antigen against P. vivax developed by Walter Reed scientists. (Forbes)
Multiple NIH Phase 2 HIV Vaccine Trials Using Vical's Technology Produce Encouraging Results Aug 23, 2007
The adenoviral vector vaccine was developed by VRC in collaboration with GenVec Inc., of Gaithersburg, Md. which also manufactured the adenoviral vector vaccine. (PR Newswire)
Genvec losses widen with major declines in revenue Aug 8, 2007
Genvec, which develops gene-based drugs and vaccines, was awarded the NIH contract to manufacture and test HIV vaccine supplies on 8,000 patients ... GenVec also lost revenue because its funding from FUSO Pharmaceutical Industries ended Dec. 31 ... Also in May, GenVec said the U.S. Patent and Trademark Office gave it two patents, including one that protects the company's method of using its most clinically advanced drug candidate TNFerade with radiation to treat solid tumors or soft-tissue... (Washington Business Journal, DC)
Vaccine Offers New Control Options For Foot-and-mouth Disease Jun 2, 2007
The vaccine is the first molecular-based FMD vaccine for cattle, developed by scientists with ARS, the Department of Homeland Security's Targeted Advanced Development unit (TAD) and GenVec, Inc., a biopharmaceutical company based in Gaithersburg, Md ... by Douglas E. Brough, senior director of GenVec's Vector Sciences. (Science Daily)
BioVeris Corp. May 16, 2007
GenVec to be included in Nasdaq biotech index - Washington Business Journal ... GenVec to be included in Nasdaq biotech index ... Gaithersburg-based GenVec, a developer of gene-based drugs and vaccines for cancer and infectious diseases, said it would be added to the index May 21. (Washington Business Journal, DC)
Semi-Annual Changes to the NASDAQ Biotechnology Index May 12, 2007
GenVec, Inc. (NasdaqGM: - ) is a biopharmaceutical company developing novel gene-based therapeutic drugs and vaccines ... GenVec is developing a therapeutic product for the treatment of locally advanced pancreatic cancer and other solid tumor cancers ... GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases. (Primezone Releases)
GenVec's malaria vaccine collaboration receives funding May 3, 2007
GenVec has amended and extended its research and development agreement with the Path Malaria Vaccine Initiative, actions that provide for up to $750,000 in additional funding through the end of this year to continue work on a new malaria vaccine. The vaccine has been developed under a multiyear agreement between Gaithersburg-based GenVec and Seattle-based Path, a nonprofit organization, currently worth up to $3 ... Under a separate agreement between GenVec and the Naval Medical Research Center,... (Washington Business Journal, DC)
Novavax finance chief resigns Apr 8, 2007
He was previously CFO at Gaithersburg-based GenVec. Church will leave Novavax later this month to accept a position with another company, Novavax says in a statement. (Washington Business Journal, DC)
GenVec to work with NIH on vaccines for RSV Mar 21, 2007
GenVec has signed a research and development agreement with the to develop vaccines for respiratory syncytial virus, also known as RSV.. The Gaithersburg-based company -- which is developing gene-based drugs and vaccines for cancer, malaria and other diseases -- says it will combine the scientific and clinical expertise of the National Institute of Allergy and Infectious Diseases with GenVec's experience in vaccine development and manufacturing ... In addition to its collaboration with the NIH... (Washington Business Journal, DC)
Gaithersburg biotech plans big stock sale Mar 5, 2007
Federal regulators have flashed GenVec the green light to sell up to $100 million worth of shares over the next two years. The ruling essentially places the registered shares on a shelf, speeding up the process of putting them up for sale if the Gaithersburg company so chooses in the next two years. (Baltimore Business Journal, MD)
GenVec raises $19.7M in stock sale Jan 2, 2007
Biopharmaceutical company GenVec has raised $19 ... Stock in GenVec (NASDAQ: GNVC) closed Dec. 22 at $2 ... Rodman & Renshaw acted as the placement agent and served as a financial adviser in connection with this transaction, GenVec says. (Baltimore Business Journal, MD)
